{"id":46016,"date":"2022-07-11T14:02:30","date_gmt":"2022-07-11T12:02:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/"},"modified":"2022-07-11T14:02:30","modified_gmt":"2022-07-11T12:02:30","slug":"meissa-vaccines-appoints-frank-glavin-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/","title":{"rendered":"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer"},"content":{"rendered":"
\n

REDWOOD CITY, Calif.–(BUSINESS WIRE)–#COVID19<\/a>—Meissa Vaccines<\/a> (\u201cMeissa\u201d), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company\u2019s Chief Scientific Officer.\n<\/p>\n

<\/a><\/p>\n

\n\u201cI am excited to welcome Frank to the Meissa leadership team,\u201d said Dr. Moore. \u201cWe are at an important stage in Meissa\u2019s growth, and Frank brings extensive, complementary experience in commercial planning, business development, and pipeline strategy to advance novel technologies in clinical development for regulatory approval. I look forward to continuing to work with Frank and the Meissa team to drive our platform and vaccine candidates forward.\u201d\n<\/p>\n

\n\u201cI\u2019ve been working closely with Marty and the team as an advisor, and I am impressed with the differentiation of Meissa\u2019s AttenuBlock platform in the vaccine space and the tremendous progress the company has made,\u201d said Mr. Glavin. \u201cThe initial clinical data from the RSV and COVID-19 programs demonstrate the enormous potential of Meissa\u2019s AttenuBlock platform to develop intranasal vaccines to protect against respiratory viruses, and we look forward to completing enrollment in these studies and reporting the data in the first half of next year.\u201d\n<\/p>\n

\nMr. Glavin was previously CEO of Orphan Technologies, which advanced two rare disease assets from the lab to the clinic culminating in a sale to Travere Therapeutics (Nasdaq: TVTX). In addition, he was the Head of Neovii Biotech North America, where he was responsible for clinical development, regulatory approval, and commercialization of the US portfolio.\n<\/p>\n

\nAbout Meissa\u2019s Intranasal RSV Vaccine Candidate<\/b>\n<\/p>\n

\nMeissa\u2019s MV-012-968, an intranasal live attenuated vaccine for RSV, is in a Phase 1c study in seronegative infants and young children (ClinicalTrials.gov Identifier: NCT04909021<\/a>). Previously reported clinical data<\/a> in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, appropriately attenuated, and stimulated RSV-specific mucosal IgA, despite pre-existing immunity to RSV. No vaccine is currently approved to protect against respiratory syncytial virus (RSV). RSV is a leading cause of respiratory infections, such as bronchiolitis and viral pneumonia, in infants.\n<\/p>\n

\nAbout Meissa\u2019s Intranasal Recombinant COVID-19 Vaccine Candidate<\/b>\n<\/p>\n

\nMeissa\u2019s MV-014-212, the company\u2019s intranasal recombinant live attenuated COVID-19 vaccine, is currently in a Phase 1 study in adults (ClinicalTrials.gov Identifier: NCT04798001<\/a>). Meissa\u2019s needle-free, intranasal COVID-19 vaccine is designed for global use to block transmission, provide durable protection, and control SARS-CoV-2 spread and variants. Previously reported preliminary clinical data<\/a> from this study show a single dose of Meissa\u2019s vaccine stimulated a nasal IgA antibody response similar to that seen after SARS-CoV-2 infection, with no serious adverse events reported and no infectious vaccine virus detected. Previously reported preclinical data<\/a> demonstrate that Meissa\u2019s intranasal COVID-19 vaccine generated both mucosal and systemic antibodies and was highly protective against wild-type SARS-CoV-2 challenge in non-human primates (NHPs).1<\/sup>\n<\/p>\n

\nAbout AttenuBlock\u2122: Meissa\u2019s Intranasal Vaccine Platform<\/b>\n<\/p>\n

\nMeissa\u2019s live attenuated intranasal vaccines are built on the company\u2019s proprietary AttenuBlock platform<\/a> to achieve appropriate attenuation, genetic stability, and optimized immunity. Injectable vaccines typically induce only serum (IgG) antibodies that circulate in the blood and are important for preventing serious lung disease. Intranasal vaccines also generate mucosal (IgA) antibodies in the nasal cavity, which are essential for blocking infection and transmission of respiratory viruses like RSV and SARS-CoV-2. Meissa\u2019s vaccine platform and intranasal vaccine strategy are uniquely designed to confer mucosal immunity that will likely reduce transmission, if compared to injectable vaccines, provide long-lasting protection, and be a part of the global solution to controlling respiratory viruses.\n<\/p>\n

\nAbout Meissa Vaccines<\/b>\n<\/p>\n

\nMeissa Vaccines was founded with a mission to protect people everywhere from life-threatening respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV). These vaccine candidates have been developed using the company\u2019s proprietary AttenuBlock\u2122 synthetic biology platform, which includes codon deoptimization and technologies exclusively licensed from Emory University and Children\u2019s Healthcare of Atlanta. Meissa\u2019s live attenuated vaccine candidates are formulated to be delivered as a single, intranasal, adjuvant-free, needle-free dose and are designed to generate a strong, durable immune response to prevent infection and disease. Meissa is headquartered in Redwood City, Calif. For more information, please visit www.meissavaccines.com<\/a>.\n<\/p>\n

\n_________________________\n<\/p>\n

\n1 <\/sup>Tioni, et al. \u201cOne mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.\u201d Posted on biorxiv on August 6, 2021: https:\/\/doi.org\/10.1101\/2021.07.16.452733<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMeissa Contacts:<\/b>
For Clinical Trials: clinicaltrials@meissavaccines.com<\/a>
Corporate Contact: Frank Glavin, CEO, Meissa Vaccines, bd@meissavaccines.com<\/a>
For Media Only: Jessica Yingling, Ph.D., Little Dog Communications Inc.<\/a>, jessica@litldog.com<\/a>, +1.858.344.8091\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

REDWOOD CITY, Calif.–(BUSINESS WIRE)–#COVID19—Meissa Vaccines (\u201cMeissa\u201d), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-46016","format-standard","category-industry"],"yoast_head":"\nMeissa Vaccines Appoints Frank Glavin Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif.–(BUSINESS WIRE)–#COVID19—Meissa Vaccines (\u201cMeissa\u201d), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-11T12:02:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220711005060\/en\/712508\/21\/Meissa_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer\",\"datePublished\":\"2022-07-11T12:02:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/\"},\"wordCount\":818,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005060\\\/en\\\/712508\\\/21\\\/Meissa_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/\",\"name\":\"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005060\\\/en\\\/712508\\\/21\\\/Meissa_Logo.jpg\",\"datePublished\":\"2022-07-11T12:02:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005060\\\/en\\\/712508\\\/21\\\/Meissa_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005060\\\/en\\\/712508\\\/21\\\/Meissa_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer - Pharma Trend","og_description":"REDWOOD CITY, Calif.–(BUSINESS WIRE)–#COVID19—Meissa Vaccines (\u201cMeissa\u201d), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-11T12:02:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220711005060\/en\/712508\/21\/Meissa_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer","datePublished":"2022-07-11T12:02:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/"},"wordCount":818,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220711005060\/en\/712508\/21\/Meissa_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/","name":"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220711005060\/en\/712508\/21\/Meissa_Logo.jpg","datePublished":"2022-07-11T12:02:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220711005060\/en\/712508\/21\/Meissa_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220711005060\/en\/712508\/21\/Meissa_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/meissa-vaccines-appoints-frank-glavin-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Meissa Vaccines Appoints Frank Glavin Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46016"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46016\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}